How Probodies Work
Our proprietary Probody™ Platform represents a disruptive approach to discovering and developing empowered antibodies to treat areas of major unmet medical need.
Probodies have the potential to expand the therapeutic window for diseases by increasing safety and unlocking efficacy.
Traditional antibodies bind to targets in both diseased and healthy tissue. This indiscriminate binding of antibodies has been correlated with significant toxicities, limiting treatment with traditional antibodies.
By design, a Probody binds to diseased tissue while the mask prevents binding to healthy tissue, thereby avoiding toxicities.
The improved target selectivity of our Probodies allows us to open a therapeutic window for high-potential but previously inaccessible targets, and to expand the therapeutic index of existing, validated targets, thereby redefining the landscape for therapeutic antibodies.
Our novel platform is enabling the development of a diversified pipeline of empowered antibodies, including Probodies and Probody drug conjugates (PDCs). The unique selectivity of Probodies expands the therapeutic window for both validated and novel targets, and has the potential to create multiple new classes of safer and more effective therapies.
Our pipeline, and the pipelines of our partners, includes therapies against cancer targets that are only addressable utilizing our Probody technology.